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Abstract 108 – Table 1. Adjusted* Hazard Ratios for TGF-β1 and OA Outcomes
Deﬁnition of OA Outcomes n Adjusted HR* p value
(knees with outcome) (95%CI)
Incident rOA (from baseline K-L<2 to K-L ≥ 2) 103 1.10 (0.46-2.63) 0.83
Incident rOA (from baseline K-L<1 to K-L ≥ 1) 94 1.04 (0.41-2.65) 0.93
Incident OST (from grade 0 to grade ≥ 1) 94 1.41 (0.56-3.56) 0.47
Incident JSN (from grade 0 to grade ≥ 1) 99 1.39 (0.50-3.88) 0.53
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 2) 86 1.36 (0.63-2.91) 0.44
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 1) 160 1.51 (0.82-2.79) 0.19
Progressive OST (increasing ≥ 1 grade from baseline OST ≥ 1) 76 0.55 (0.24-1.26) 0.16
Progressive JSN (increasing ≥ 1 grade from baseline JSN ≥ 1) 84 1.40 (0.64-3.03) 0.40
*Adjusted for age, race, gender, and body mass index.
6.1±1.3 years. There were no signiﬁcant interactions by race or
gender. The hazard ratios (Table) show no signiﬁcant relationships
between higher serum TGF-β1 and incident rOA, OST, or JSN
at the knee before or after adjustment. The odds of progressive
rOA by either K-L deﬁnition were 40- 50% higher in association
with higher serum TGF-β1 levels, but this association was not
statistically signiﬁcant. There was an apparent reduction in OST
progression with higher lnTGF-β1, also not statistically signiﬁcant.
Conclusions: Serum TGF-β1 levels do not predict development
of incident rOA, OST, or JSN in this longitudinal, population-based
study including AA and Caucasian men and women. The ﬁnding of
increased rOA K-L progression with higher serum TGF-β1 levels
did not reach statistical signiﬁcance, even in this largest study to
date of this biomarker, making it unlikely that serum TGF-β1 will
be a robust, stand-alone biomarker for future studies.
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EX VIVO CHARACTERIZATION OF THREE NEW
METALLOPROTEINASE-DERIVED NEOEPITOPIC
BIOMARKERS OF TYPE II COLLAGE
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Purpose: Type II collagen is the major collagen of the articular
cartilage and it is gradually degraded during the pathogenesis of
osteoarthritis (OA). Measurement of collagen type II degradation
fragments may be associated with the progression of Osteoarthritis
(OA). It is appreciated that aggrecan degradation is a combina-
tion of MMP and aggrecanase activity, resulting in a distinct and
protease speciﬁc temporal release pattern, with aggrecanase ac-
tivity at early time-points and MMP activity at later time-points.
The release of collagen type II is less understood with respect
to the temporal release pattern, and the different proteolytic pro-
teases associated with that. We therefore identiﬁed three novel
MMP-mediated collagen type II degradation fragments of collagen
type II, and developed assays for that. We compared the release
pattern to that of CTX-II.
Methods: Human type II collagen (puriﬁed) and human articu-
lar cartilage was digested with a mix of MMPs. The digested
was analyzed on LC-MS/MS and peptide fragments were identi-
ﬁed/mapped by Mascot database search. Three neoepitopic se-
quences were chosen, synthesized and used as immunogen.
Fusions were made from the spleen of good-titer mice. After
cloning and screening, the best clones were chosen and the
monoclonal antibodies were puriﬁed and entered assay devel-
opment. All assays were designed as follows: 1) biotin-peptid
on streptavidin plates, 2) samples or standard, 3) Primary anti-
body, and 4) secondary HRP-antibody. Bovine explants cultures
treated with proinﬂammatory cytokines were used for testing the
biomarkers for native reactivity. Experiment including different pro-
teases inhibitors were conducted to validated the origin of the new
biomarkers. Established markers were measured in paralled for
comparison. Furthermore; the antibodies were tested for localiza-
tion by immunohistochemistry.
Results: Three assays were developed; CIIM538, CIIM1027 and
CIIM1053. All three assays were optimized in respect to incubation
buffer, time and temperature, as well as antibody concentrations.
Following technical speciﬁcation were established (on average):
Range - 1-500 ng/ml, lower detection limit 0.2 ng/ml, dilution recov-
ery 95-120%, intra- and inter-assay CVs < 6% and 11%, respec-
tively. Measuring time-dependent release of the new biomarkers
showed that the new type II collagen assays could proﬁle the
degradation of cartilage as a function of time. The releases of
CIIM538 and CIIM1027 are signiﬁcantly increased when treated
with O+T for 13-15 days. These results show similar pattern to the
release observed when we measure MMP-generated aggrecan
fragments (342-G2). The third MMP-derived marker, CIIM1053,
seems to displace the release to later time points, which resem-
bles the release pattern of CTX-II. Furthermore the signal was
inhibited when MMP inhibitor, but not other protease inhibitors,
was added to the cultures.
Conclusions: We have developed three new biomarkers of type II
collagen, speciﬁc for MMP neoepitopic sites in the helical region.
These three assays display different release patterns; suggesting
the use of these in proﬁling different stages or processes of carti-
lage degradation. The combination of several markers is needed
for the understanding biological processes in preclinical settings,
and these assay aid the understanding to distinct and relevant dis-
ease related processes. In a near future, we will introduce clinical
sample to these assays in hope of developing important clinical
tools.
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Purpose: Quantitative determination of cartilage degradation is
important information for the assessment of patients with joint dis-
eases, however, until now in vitro diagnostic products have failed
to provide the necessary sensitivity and speciﬁcity. We therefore
wanted to investigate the clinical utility of a series of new sandwich
immunoassays quantitating different pools of aggrecan fragments
carrying neo-epitopes generated by the proteolytic cleavage of
aggrecanase and matrix metalloproteinases (MMPs).
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Methods: Blood samples were collected from patients with
rheumatoid arthritis (n=33) and healthy controls (n=33), serum
was harvested and stored at -20°C until testing. Aggrecan frag-
ments carrying the aggrecanase-derived neo-epitope NITEGE373
was determined using the G1-NITEGE373 ELISA, correspond-
ing fragments carrying the 374ARGSV neo-epitope using the
374ARGSV-G2 ELISA, and ﬁnally total aggrecan was determined
using the G1/G2 ELISA.
Results: We determined the concentration of G1-373NITEGE
aggrecan fragments in human serum and found 989 ng/ml ±
238 ng/ml (mean ± SD) and 310 ng/ml ± 42 ng/ml in patients
with RA and controls, respectively. This corresponds to a 3-fold
increase, which was highly signiﬁcant (p=0.004). In parallel, we
determined the concentration of the 374ARGSV-G2 fragments,
which also is derived from aggrecanase-cleavage of aggrecan,
however, no difference between RA and controls was detected.
Finally, circulating levels of total aggrecan, as determined by
the G1/G2 ELISA, was suppressed in RA patients vs controls
(p=0.0003), whereas MMP-derived fragments determined in the
342FFGVG-G2 ELISA was similar in the two groups.
Conclusions: We conclude, that whereas the total circulating
levels of aggrecan fragments carrying the G1 and/or G2 do-
mains is suppressed in RA patients, then the serum concentration
of the aggrecanase-derived aggrecan neo-epitopes, but not the
MMP-mediated, are elevated in in patients with RA. Circulating
aggrecanase-mediated aggrecan fragments may be more sensi-
tive than MMP-derived fragments to detect cartilage damage in
RA.
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SERUM cartilage oligomeric matrix protein
CONCENTRATION CAN PREDICT SUBSEQUENT MRI
CHANGES OF EARLY KNEE OA
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Purpose: Serum measures of cartilage oligomeric matrix protein
(COMP), a marker of cartilage degradation, may be a promising
tool for evaluating OA severity or perhaps predicting disease
progression. Here we use COMP to predict the changes of early
knee OA detected by peripheral MRI during a two year follow up
study.
Methods: 33 patients (8 men and 25 women) aged 45-65 years
with chronic (>2 month duration) knee pain and diagnosed with
early knee osteoarthritis were chosen and followed for 24 months.
A blood sample was obtained at baseline and the serum concen-
tration of COMP was determined by immunoassay. MRI scans (3D
Gradient Echo for cartilage evaluation) for the symptomatic knee
were performed at baseline, 6 months, 12 months and 24 months
later. A trained radiologist semiquantitatively graded cartilage on a
scale of 0-4 in each of the medial tibia, lateral tibia, medial femur
and lateral femur. The maximum score that can be obtained is 24.
The baseline MRI cartilage score of all patients is ranged from 7
to 14.
Results: A signiﬁcant, positive regression was found between
baseline serum COMP concentration and the changes of MRI
cartilage scores over 24 months (R2=44.5%, P<0.001).
Conclusions: These results suggest that higher COMP at base-
line in patients with early OA could reﬂect increased cartilage
degeneration over time relative to those with lower COMP levels.
These ﬁndings support the hypothesis that a marker of cartilage
degradation may predict future cartilage degeneration.
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ANALYSIS OF A BROAD SPECTRUM OF URINARY AND
SERUM BIOMARKERS IN A LARGE COHORT OF PATIENTS
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Purpose: Biomarkers to diagnose OA in an early stage and/or
to predict its course would be of great value. Therefore, we se-
lected a broad spectrum of commercially available serum and
urinary biomarkers representative of cartilage, bone and syn-
ovium metabolism for evaluation in the Cohort Hip & Cohort Knee
(CHECK). This cohort consists of 1002 participants with pain
and/or stiffness of knee and/or hip, aged 45-65 yrs, and who had
never or no longer than 6 months before visited their physician
for these symptoms for the ﬁrst time. Hip and knee radiographs
as well as clinical parameters and multiple questionnaires are
evaluated at regular intervals. Furthermore, blood (plasma and
serum; s) and urine (u) samples (multiple aliquots of all three)
are collected at 0, 2, 5, 8, and 10 yrs. Samples are obtained in
10 medical centers and processed in the same central laboratory,
all according to strict protocols. Biomarker measurement in these
samples provides a unique opportunity to study the diagnostic
and prognostic properties of biomarkers in early-stage OA. Base-
line biomarker measurement has recently been completed. The
data set is huge, speciﬁcally in combination with all patient char-
acteristics and longitudinal radiographic and clinical data. Before
relations are calculated we have to be sure about the quality of
the biomarker data set. This abstract covers this issue.
Methods: Baseline samples were thawed for the ﬁrst time.
Commercially available ELISA assays were performed to mea-
sure uCTX-II, uCTX-I (ImmunoDiagnostic Systems Ltd.), uNTX-I
(Wampole Laboratories), sCOMP (Anamar Med AB), sOC (IDS),
sHA (Corgenix Inc.), sPIIANP (Millipore Corp.), sCS846, and
sC1,2C (IBEX) and RIA assays for sPINP and sPIIINP (Orion
Diagnostica). All kits were purchased without commercial involve-
ment and for each biomarker kits were from the same badge.
A serum and urine pool were created from several OA patients and
aliquoted. At each of the assay days an aliquot was thawed and
included at multiple places in the assay plates. Each biomarker
was measured in all samples by the same technician in 8 days in
a period of 6 wks using 14 kits.
Results: Quality control as was performed by using a randomly
distributed pool sample, controls as supplied by manufacturers,
and blank samples in-between patient samples was unremarkable,
except for the COMP assay. The COMP assay’s pool sample
showed a remarkably variable biomarker concentration within and
between assay plates.
